Copyright
©The Author(s) 2024.
World J Gastroenterol. Mar 7, 2024; 30(9): 1073-1095
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1073
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1073
Endocrinopathy | Interventions | Comments | Ref. |
Diabetes mellitus | Therapeutic goals: Compensated cirrhosis: FPG 4.44-7.22 mmol/L, PP glucose < 9.99 mmol/L; decompensated cirrhosis: FPG 5.00-8.32 mmol/L, PP glucose < 11.10 mmol/L, and pre-meal glucose 5.55-11.10 mmol/L | [28,50] | |
Metformin | Maximum 1500 mg/d. Do not use in hypoxemia, dehydration, sepsis, or Child-Pugh B and C | [50,109] | |
Sulfonylureas | Can be used in low doses in Child-Pugh A. Contraindicated in Child-Pugh B and C | [28,50,100,109] | |
Meglitinides | Do not use repaglinide. Nateglinide can be used in Child-Pugh A and B in lower doses | [28,50] | |
Thiazolidinediones | Do not use rosiglitazone. Pioglitazone can be used in Child-Pugh A | [28,50,109] | |
DPP-4 inhibitors | Can be used in Child-Pugh A without modifying the dose, except for vildagliptin. Use with caution in Child-Pugh B, but not in Child-Pugh C | [50,109] | |
GLP-1 RA | Can be used in Child-Pugh A without modifying the dose. Use with caution in Child-Pugh B, but not in Child-Pugh C, due to limited data Unknown for Tirzepatide and Retatrutide | [50,109] | |
SGLT-2i | Can be used in Child-Pugh A, starting with lower doses. Use with caution in Child-Pugh B but avoid in Child-Pugh C due to the risk of dehydration and hypotension | [28,109] | |
Alpha-glucosidase inhibitors | Can be used in Child-Pugh A and B but are not recommended in Child-Pugh C | [50,109] | |
Insulin | Reserve for those unable to use oral medications, fail to achieve adequate glycemic control, or in cases of sepsis, encephalopathy, bleeding, or acute kidney injury. It is the choice in DM and decompensated LC; start with 0.1-0.2 IU/kg/d (higher if blood glucose is very high). Adjust the dose based on blood glucose, varying by 2 units every 3 d if necessary. Add rapid-acting insulin if goals are not achieved, starting with 4 units or 10% of basal insulin and increasing by 1-2 units every 3-4 d as needed. Prefer analog insulins for a lower risk of hypoglycemia | [28,109] | |
Statins | Generally recommended for males, individuals with diabetes, and those with a high Fibrosis-4 index at the beginning of the study | [140] | |
Liver transplantation | The worse the beta cell function, the less effective liver transplantation will be in achieving DM remission | [17] | |
Hypoglycemia | New episodes should be prevented by adjusting the dose or modifying the drugs used | ||
15-20 g of oral glucose | For conscious patients. Reassess in 15 min and repeat if necessary | [56,142,143] | |
Parenteral glucagon | For unconscious patients or those with severe hypoglycemia | [56,142,143] | |
Sarcopenia | Nutritional support | Caloric intake of 35-40 kcal/kg and protein intake of 1.2-1.5 g/kg. Eat at intervals of 2-3 h and include a bedtime snack with 50 g of carbohydrates and 20 g of protein | [145,146] |
BCAA | Long-term supplementation at a dose of 0.25 g/kg/d | [146] | |
Exercise | Recommended moderate-intensity aerobic and resistance exercises | [21] | |
Others | Treatments to reduce ammonia, hormonal supplements, and myostatin inhibitors are still under study | [21,22,147] | |
Male hypogonadism | Testosterone supplementation | Considered adjunctive therapy to improve frailty | [148] |
PDE-5i | Sildenafil, tadalafil, avanafil, and vardenafil are FDA-approved and can be used in Child-Pugh A and B at lower doses | [24] | |
Liver transplantation | Restores physiological levels of testosterone, estradiol, SHBG, gonadotropins, and prolactin | [45] | |
Female hypogonadism | Lifestyle modifications and psychological support should be included | [24] | |
Contraception | In compensated cirrhosis, hormonal contraceptives can be used without restriction, but in decompensated cirrhosis, the risks outweigh the benefits | [152] | |
Liver transplantation | Restores physiological levels of testosterone, estradiol, SHBG, gonadotropins, and prolactin | [45] | |
Overt hypothyroidism | Levothyroxine | Immediate treatment per general recommendations, considering higher doses might be necessary due to malabsorption | [67,153] |
Subclinical hypothyroidism | Levothyroxine | Treatment per general recommendations. Liver function is not part of the treatment decision | [72] |
Euthyroid sick syndrome | Hormonal treatment is not recommended | [72] | |
Hyperthyroidism | Thiamazole | Recommended starting dose of 20mg in Child-Pugh A with continuous monitoring of liver function. Not recommended in Child-Pugh B and C | [154-156] |
Propylthiouracil | Its use is not recommended | [67] | |
Definitive treatments | Radioactive iodine therapy or thyroidectomy based on patient’s need and clinical condition | [67] | |
Liver transplantation | Not recommended to restore thyroid function | [45] | |
Hepatic bone disease | Calcium | 1000-1500 mg/d, taken with food | [77,158,160] |
25-OH vitamin D | Supplement only if there is a deficiency of vitamin D | [38] | |
PTH | There is not enough evidence in advanced cirrhosis | [158] | |
Bisphosphonates | Parenteral use is recommended | [158] | |
Raloxifene | There is not enough evidence in cirrhosis | [77,158] | |
Adrenal insufficiency | Hydrocortisone | Critically ill patients: 200-300 mg/d intravenously, divided into 3 to 4 doses, with progressive titration based on the patient’s clinical evolution; non-critically ill patients without symptoms: 15-20 mg/d orally, divided into 2 doses, only if persistent hypotension and hyponatremia are present | [86,87,91,163,164] |
Growth hormone dysfunction | GH | If GH deficiency is demonstrated: 0.4-0.5 mg/d (< 30 years), 0.2-0.3 mg/d (30-60 years), 0.1-0.2 mg/d (> 60 years), with dose titration to maintain IGF-1 within the standard deviation of -2 to 2. | [92,94,95,165-168] |
Secondary hyperaldosteronism | Loop diuretics | High doses of furosemide (up to 160 mg/d) in cases without renal insufficiency, although with limited effectiveness | [46] |
Mineralocorticoid receptor antagonists | Spironolactone (up to 400-600 mg/d). Eplerenone is more selective with fewer side effects. Finerenone is a potent and selective non-steroidal antagonist | [46,171] |
- Citation: Quiroz-Aldave JE, Gamarra-Osorio ER, Durand-Vásquez MDC, Rafael-Robles LDP, Gonzáles-Yovera JG, Quispe-Flores MA, Concepción-Urteaga LA, Román-González A, Paz-Ibarra J, Concepción-Zavaleta MJ. From liver to hormones: The endocrine consequences of cirrhosis. World J Gastroenterol 2024; 30(9): 1073-1095
- URL: https://www.wjgnet.com/1007-9327/full/v30/i9/1073.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i9.1073